Mevacor Articles
Statins may be useful for aching back
2 March 2009
Lovastatin regimen shrinks patient tumor 70%
8 December 2008
Lovastatin achieves melanoma remission
1 September 2008
Rx-to-OTC switching making comeback
21 April 2008
Abbott's Simcor gets FDA approval as cholesterol control treatment
25 February 2008
FDA issues "non-approvable" letter for Merck & Co
11 February 2008
FDA panel says no to OTC statin Mevacor
24 December 2007
Merck & Co's OTC Mevacor to go before FDA in Dec
5 November 2007
Bently gets Spanish OK for five generic drugs
5 November 2007
Kos' 3rd-qtr 2006 income rises 17%
27 November 2006
Andrx' 4th-qtr 2005 income drops 16%
27 March 2006
Japan stock market week to June 10
20 June 2005
Statins, the next to go OTC?
30 May 2005
Barr gets FDA approval for generic Niaspan
9 May 2005
First Horizon buys two Andrx drugs for $85M
14 March 2005
FDA panel rejects Merck & Co/J&J's application for OTC Mevacor
24 January 2005
US Medicare discount Rx plan web site introduces price comparisons
27 September 2004
Statins to open door for more US OTC switches?
20 September 2004
Statins may prevent HIV from replicating
23 August 2004
FDA set to speed US Rx-OTC switches?
12 July 2004
Kos settles with Andrx over Advicor
21 June 2004
Novartis to invest in Polish generics
24 May 2004
Are statins next for OTC switching?
10 May 2004
Kos takes Barr to court over Niaspin patent
12 April 2004
Merck KGaA/Kos' Niaspan cleared in EU
2 February 2004
Tokyo pharma stocks - week to Nov 10
17 November 2003
Stock Commentary - Tokyo
17 November 2003
Kos and Takeda sign US co-promotion deal
10 November 2003
Sales near flat at Merck KGaA in third qtr, generics grow as pipeline is restructured
3 November 2003
Merck KGaA gets UK approval for Niaspan
23 June 2003
Some TCs poised for Rx-to-OTC switches: new report
24 February 2003
Strong 4th-quarter operating results at Merck KGaA on flat sales
24 February 2003
New use for Altocor approvable, says FDA
15 July 2002
Andrx gets US OK for branded lipid-lowerer
1 July 2002
More Zetia trials support efficacy
20 May 2002
Kos Pharma sees 1st qtr revenues leap 136%
20 May 2002
US push for generics of "gold-standard" drugs
25 February 2002
Andrx gets tentative OK for lovastatin brand
11 February 2002
Kos launches Advicor in USA
4 February 2002
Genaissance completes enrollment in STRENGTH II study.
21 January 2002
Teva has final FDA OK for generic Mevacor
7 January 2002
Merck, S-P file in USA for cholesterol drug
7 January 2002
Teva has final FDA OK for generic Mevacor
19 December 2001
Geneva returns drug rights to Andrx
25 October 2001
Genaissance begins second STRENGTH study
19 October 2001
Kos Pharma files $200 million shelf offer
3 September 2001
Stock Commentary - New York
28 June 2001
Further relief for Merck & Co's Mevacor
22 June 2001
Stock Commentary - New York
21 June 2001
Unprecedented growth forecast for generics
18 June 2001
Kos names new dyslipidemia drug Advicor
25 April 2001
Andrx files NDA for new lovastatin form
5 April 2001
Andrx completes $29 million C Tex purchase
26 January 2001
Tentative OK for generic lovastatin
21 December 2000
Andrx to acquire C Tex Pharmaceuticals
20 November 2000
Kos and DuPont file for combo cholesterol drug OK
28 September 2000
FDA says Mevacor should not go OTC, at least for now
14 July 2000
Kos/DuPont alliance cleared by FTC
7 June 2000
Stock Commentary New York
17 February 2000
Mevacor approved for primary prevention
18 March 1999
Merck disappointment as highly-touted antidepressant stalls
26 January 1999
HMO Stops Supplying Zantac, Xanax, Mevacor
8 December 1998
Healthy Third-Quarter Growth For US Drug Majors
22 October 1998
India Acts On Chinese Drug "Dumping"
7 October 1998
W-L's Lipitor "Will Be World Top-Seller In 2005"
3 August 1998
US Drug Stocks Plummet After Merck Disappoints
23 July 1998
US Quarterly Financial Results Round-Up
23 April 1998
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
